Scott Silverman
Atlanta
Summary
Accomplished business development executive with 15+ years in the pharmaceutical and biotech sectors, driving growth and partnerships across rare diseases and large-market therapeutic areas. Proven track record of delivering over $1B in deal value through M&A, licensing, and strategic alliances. Recognized for forging high-value collaborations with global pharma, biotech innovators, and leading research institutions. Skilled in financial modeling, due diligence, and deal execution, with a strong ability to align cutting-edge science with business strategy to unlock corporate growth.
Overview
18
18
years of professional experience
Work History
Head of Business Development
Saol Therapeutics
Atlanta
12.2017 - Current
- Advanced from Manager to Senior Director through multiple promotions, recognized for consistent performance, strategic execution, and leadership excellence.
- Led rare disease strategic partnerships, licensing, and acquisitions to expand the pipeline and diversify the portfolio.
- Executed divestments that returned value to shareholders and optimized the balance sheet, positioning the company to advance its pipeline.
- Built and led cross-functional teams across R&D, regulatory, and commercial functions to evaluate and execute opportunities.
Manager, Business Development
Arbor Pharmaceuticals
Atlanta
04.2015 - 12.2017
- Executed $600M+ in licensing and acquisition transactions, including the $467M acquisition of Xenoport, Inc.
- Led due diligence, valuation, and financial modeling efforts across multiple deals.
- Collaborated with executive leadership to identify and assess growth opportunities.
Manager, Healthcare/Corporate Compliance
Arbor Pharmaceuticals
Atlanta
05.2013 - 04.2015
Associate Manager, Regulatory Affairs
Merial (acquired by Boehringer Ingelheim)
Atlanta
05.2011 - 05.2013
Regulatory Affairs Specialist, Pharmaceutical New Projects
Merial (acquired by Boehringer Ingelheim)
Atlanta
06.2008 - 05.2011
Veterinary Technical Solutions Specialist
Merial (acquired by Boehringer Ingelheim)
Atlanta
04.2007 - 06.2008
Education
Bachelor of Science - Animal Science
University of Georgia
GA05-2024
MBA - Business Administration
South University
Atlanta, GA12-2012
Skills
Business Development & Licensing Strategic Partnerships M&A Pharmaceutical & Biotech Industry Expertise Rare Disease Financial Modeling & Valuation Due Diligence Cross-Functional Leadership Negotiation and deal structuring
Timeline
Head of Business Development
Saol Therapeutics
12.2017 - Current
Manager, Business Development
Arbor Pharmaceuticals
04.2015 - 12.2017
Manager, Healthcare/Corporate Compliance
Arbor Pharmaceuticals
05.2013 - 04.2015
Associate Manager, Regulatory Affairs
Merial (acquired by Boehringer Ingelheim)
05.2011 - 05.2013
Regulatory Affairs Specialist, Pharmaceutical New Projects
Merial (acquired by Boehringer Ingelheim)
06.2008 - 05.2011
Veterinary Technical Solutions Specialist
Merial (acquired by Boehringer Ingelheim)
04.2007 - 06.2008
Bachelor of Science - Animal Science
University of Georgia
MBA - Business Administration
South University
Similar Profiles
Anthony J. Varano, Jr.Anthony J. Varano, Jr.
Co-Founder, CEO & Investor at Cervello Therapeutics & Resero TherapeuticsCo-Founder, CEO & Investor at Cervello Therapeutics & Resero Therapeutics
Amber AlstonAmber Alston
Manufacturing Associate at Moderna TherapeuticsManufacturing Associate at Moderna Therapeutics
Monica ZhangMonica Zhang
Scientist I, Cell Biology at Iksuda TherapeuticsScientist I, Cell Biology at Iksuda Therapeutics
Alexander BravoAlexander Bravo
Frozen and Dairy Associate at TargetFrozen and Dairy Associate at Target
Arioth AzamArioth Azam
Cleaner at Elia MondragonCleaner at Elia Mondragon